Loading...
Loading...
KPTI| Name | Value |
|---|---|
| Revenues | 42.8M |
| Cost of Revenue | 1.6M |
| Gross Profit | 41.2M |
| Operating Expense | 69.3M |
| Operating I/L | -28.1M |
| Other Income/Expense | 52.0M |
| Interest Income | 1.9M |
| Pretax | 23.9M |
| Income Tax Expense | 0.1M |
| Net Income/Loss | 23.8M |
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company specializing in the discovery, development, and commercialization of drugs targeting nuclear export for cancer and other diseases. The company's main focus is on its novel Selective Inhibitor of Nuclear Export (SINE) compounds, which function by inhibiting the nuclear export protein XPO1. Its lead compound, XPOVIO, is used in combination therapies for the treatment of multiple myeloma and diffuse large B-cell lymphoma. Karyopharm Therapeutics generates revenue through the development, licensing, and commercialization of its SINE compounds for oncology indications in various regions, including Europe and Latin America.
